A Phase II Study of the Efficacy of Rabbit Anti-thymocytes Globulin (rATG) in Patients With Low and Intermediate-1 Risk Myelodysplastic Syndrome.

Trial Profile

A Phase II Study of the Efficacy of Rabbit Anti-thymocytes Globulin (rATG) in Patients With Low and Intermediate-1 Risk Myelodysplastic Syndrome.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2013

At a glance

  • Drugs Antithymocyte globulin (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms RISE
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 30 Oct 2009 Planned end date changed from Dec 2012 to Jul 2009 as reported by ClinicalTrials.gov.
    • 14 Oct 2009 Actual patient number (16) added as reported by ClinicalTrials.gov.
    • 29 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top